FMP
Immunome, Inc.
IMNM
NASDAQ
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
16.6 USD
-0.58 (-3.49%)
About
ceo
Dr. Clay B. Siegall Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://immunome.com
exchange
NASDAQ
Description
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
CIK
0001472012
ISIN
US45257U1088
CUSIP
45257U108
Address
665 Stockton Drive
Phone
610 321 3700
Country
US
Employee
37
IPO Date
Oct 2, 2020
Key Executives
